Answer
The safety and efficacy of Gazyvaro (obinutuzumab) in children and adolescents under 18 years have not been established, and no data are available.
Sources for this answer
- Gazyvaro 1,000 mg concentrate for solution for infusionRoche Products Limited · emc · SmPC §4.2 Posology and method of administration · Version 20Document updated
Sources checked